This is the first companion diagnostic to detect gene fusions across all solid tumors; Caris expects to submit for Pre-Market Approval later this year Caris Life Sciences, a leading innovator in molecular...
Read More »Ignyta Announces Approval of an Investigational Device Exemption (IDE) for its RNA Sequencing based Companion Diagnostic Assay
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its RNA-based companion diagnostic, next-generation sequencing (NGS) assay (Trailblaze Pharos™). The ...
Read More »